MT-2990 / Mitsubishi Tanabe - LARVOL DELTA

An Exploratory Study of MT-2990 in Patients With AAV (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Mitsubishi Tanabe Pharma Corporation | Trial completion date: Aug 2025 ➔ Feb 2026 | Trial primary completion date: Aug 2025 ➔ Feb 2026

Trial completion date • Trial primary completion date • Vasculitis

An Exploratory Study of MT-2990 in Patients With AAV (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Mitsubishi Tanabe Pharma Corporation | Initiation date: Jan 2024 ➔ Jun 2024

Trial initiation date • Vasculitis

An Exploratory Study of MT-2990 in Patients With AAV (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: Mitsubishi Tanabe Pharma Corporation | Not yet recruiting ➔ Recruiting

Enrollment open • Vasculitis

An Exploratory Study of MT-2990 in Patients With AAV (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Mitsubishi Tanabe Pharma Corporation

New P1 trial • Vasculitis

Safety and Efficacy Study of MT-2990 in Women With Endometriosis (clinicaltrials.gov) - P2; N=76; Completed; Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.; Active, not recruiting ➔ Completed

Clinical • Trial completion • Endometriosis • Gynecology • Pain

Safety and Efficacy Study of MT-2990 in Women With Endometriosis (clinicaltrials.gov) - P2; N=76; Active, not recruiting; Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.; Trial completion date: Aug 2021 ➔ Nov 2021

Clinical • Trial completion date • Endometriosis • Gynecology • Pain

Safety and Efficacy Study of MT-2990 in Women With Endometriosis (clinicaltrials.gov) - P2; N=76; Active, not recruiting; Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Endometriosis • Gynecology • Pain

Safety and Efficacy Study of MT-2990 in Women With Endometriosis (clinicaltrials.gov) - P2; N=76; Recruiting; Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.; Trial completion date: Feb 2021 ➔ Aug 2021; Trial primary completion date: Sep 2020 ➔ Mar 2021

Clinical • Trial completion date • Trial primary completion date • Endometriosis • Gynecology • Pain

Newly added product (Mitsubishi Tanabe Press Release) - P1, Immunology

Pipeline update • Immunology

Safety and Efficacy Study of MT-2990 in Women With Endometriosis (clinicaltrials.gov) - P2; N=76; Recruiting; Sponsor: Mitsubishi Tanabe Pharma Development America, Inc.

Clinical • New P2 trial

A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients (clinicaltrials.gov) - P1; N=75; Completed; Sponsor: Mitsubishi Tanabe Pharma Corporation; Active, not recruiting ➔ Completed

Clinical • Trial completion